A Slow-Cycling LGR5 Tumor Population Mediates Basal Cell Carcinoma Relapse After Therapy

    October 2018 in “ Nature
    Adriana Sánchez‐Danés, Jean‐Christophe Larsimont, Mélanie Liagre, Eva Muñoz‐Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, Véronique Del Marmol, Josep Tabernero, Cédric Blanpain
    Studysummary This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results